-
Burkholderia cepaciaHelgi Karl Engilbertsson25. febrar 2004
-
Burkholderia cepacia
skingarSepsisPneumoniaMeningitisCellulitisPeritonitisEndocarditisPericarditisCholangitisSeptic
arthritisUrinary tract infections
-
Medically Important PseudomonadsrRNA homology group I-VGr. I
Pseudomonas, 6 tegGr. IIa Burkholderia, a.m.k. 22 tegGr. IIb
Ralstonia, 4 tegGr. IIc Oxalobacter, 1 tegGr. IId Pandorae, 4
tegGr. III Comamonas, 2 tegGr. IV Brevundimonas, 2 tegGr. V
Stenotrophomonas, 2 teg
-
MicrobiologyGram-negatfur
stafurExtracellulerAerobicNon-fermentiveCatalaseFlagella2-4
circular replicons sta circular chromosomesErfitt a einangraRktun
srhfu media
-
Burkholderia cepacia
-
Burkholderia cepaciaPseudomonas cepacia var lst fyrst ri 1950 af
Walter Burkholder (Cornell University plant pathologist ), sem
plntupathogen. Veldur rotnun lauk (latna, cepia)Siar kemur ljs a
tkfris human pathogenarnir P. Kingii og P. Multivarans voru smu
tegundar.Sustu 10 r komi ljs vi taxonmskar rannsknir stofn baktera,
Burkholder cepacia complex
-
Burkholder cepacia complexMismunandi genotypur me mjg svipaar
phenotypurGenomovar I-IXB. cepaciaB. multivoransB. cenocepaciaB.
StabilisB. VietnamiensisB. DolosaB. AmbifariaB. AnthinaB.
pyrrocinia
-
Burkholder cepaciaFinnst
va:VatniJarvegiDrumMnnumSptalaumhverfiKranavatnInnavlarDialysuvlarStthreinsivkvaIV
lausnirCatheterarOg fleira
-
Burkholderia cepacia skingarTkifrisskillAlgengast hj sjklingum
me undirliggjandi sjkdmaCystic fibrosis3,5 % CF sjklinga USA20-30%
skinga enda me bacteremiu og dauaChronic granulomatous
diseasenmisbldumDMMalignancyHjartabilunCOPD
-
Burkholderia cepacia pathogenesisVirulence
faktorarLyfjanmiAdherance vi
plastExoenzymeElastasiGelatinasiAdhesinResistance to nonoxative
killing of neutrophilsIntracellular
survivalSiderophoresHemolysinExopolysaccharidePiliFlagella
-
Burkholderia cepacia pathogenesisFinnast helst
ndunarvegiColonisering frekar en sking yfirleittSking getur leitt
tilNecrotizing pneumoniaBacteremiuEcthyma gangrenosumDICSeptsks
shockMultible organ dysfunction syndrome
-
Ecthyma gangrenosum
-
Burkholderia cepacia lyfjanmiBeta-laktamasiPenicilln
resistanceDihydrofolate reductasiTrimethoprim resistanceAntibiotic
efflux pumpChloramphenicol, quinolone og trimethoprim
resistanceYtri himnu gegndrpiQuinolone resistanceBreyting bindista
lyfja
-
Burkholderia cepacia meferCystic FibrosisMinocycline 33%
nmiMeropenem 28%Chloramphenicol/Minocycline
49%Chloramphenicol/Ceftazidime 26%
-
Burkholderia cepacia meferBacteremiaCeftazidime
(95%)Piperacillin (93%)Minocycline (85%)Cefotaxime
(82%)CiprofloxacinImipenemMeropenemQuinolonesTrimethoprimChloramphenicol
-
MIC = Minimum inhibitory concentrationMIC breakpoints for
resistance: Piperacillin 128 g/ml, Ceftazidime 32 g/ml, imipenem 16
g/ml, gentamicin 16 g/ml, minocycline 16 g/ml, Ciprofloxacin 4
g/ml
AntibioticMIC (g/ml)50%MIC (g/ml)90%Resistant isolates
(%)Piperacillin8646.1Ceftazidime483.0Imipenem41621.2Gentamicin64>128100Minocycline486.1Ciprofloxacin123.0
-
Capsule: 90 teg. Antiphagocytic.Adherence: Prtein sem tengjast
samgildum tengjum vi prteingrind bakteruveggsins. Tengist gegnum
essi prtein sykrungum frumuhimnu hsilsins, ea vitaka platelet
activating factor.
